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Objective: To determine if injection of vitamin K3 in
an acupuncture point is optimal for the treatment of
primary dysmenorrhoea, when compared with 2 other
injection treatments.
Setting: A Menstrual Disorder Centre at a public
hospital in Shanghai, China.
Participants: Chinese women aged 14–25 years with
severe primary dysmenorrhoea for at least 6 months
not relieved by any other treatment were recruited.
Exclusion criteria were the use of oral contraceptives,
intrauterine devices or anticoagulant drugs, pregnancy,
history of abdominal surgery, participation in other
therapies for pain and diagnosis of secondary
dysmenorrhoea. Eighty patients with primary
dysmenorrhoea, as defined on a 4-grade scale,
completed the study. Two patients withdrew after
randomisation.
Interventions: A double-blind, double-dummy,
randomised controlled trial compared vitamin K3
acupuncture point injection to saline acupuncture point
injection and vitamin K3 deep muscle injection.
Patients in each group received 3 injections at a single
treatment visit.
Primary and secondary outcome measures: The
primary outcome was the difference in subjective
perception of pain as measured by an 11 unit Numeric
Rating Scale (NRS). Secondary measurements were
Cox Pain Intensity and Duration scales and the
consumption of analgesic tablets before and after
treatment and during 6 following cycles.
Results: Patients in all 3 groups experienced pain
relief from the injection treatments. Differences in NRS
measured mean pain scores between the 2 active
control groups were less than 1 unit (−0.71, CI −1.37
to −0.05) and not significant, but the differences in
average scores between the treatment hypothesised to
be optimal and both active control groups (1.11, CI
0.45 to 1.78) and (1.82, CI 1.45 to 2.49) were
statistically significant in adjusted mixed-effects
models. Menstrual distress and use of analgesics were
diminished for 6 months post-treatment.
Conclusions: Acupuncture point injection of vitamin
K3 relieves menstrual pain rapidly and is a useful
treatment in an urban outpatient clinic.
Trial registration number: NCT00104546;
Results.
INTRODUCTION
Dysmenorrhoea is highly prevalent and a
major cause of activity restriction and school
absence among young women worldwide.1 2
Primary dysmenorrhoea is a painful men-
strual cramping of the uterus without identi-
fiable organic pathology that affects as many
as 85% of women, 20% of whom describe
their pain as severe.3 4 The initial onset of
primary dysmenorrhoea is usually shortly
after menarche, 6–12 months after ovulatory
cycles begin. High levels of uterine prosta-
glandins, a hormone associated with uterine
cramping, abdominal pain and contraction
of muscular tissue, have been identified as a
substantial contributing factor to the pain
Strengths and limitations of this study
▪ The results of this trial document the efficacy of
a treatment in use for over 40 years at a high-
volume Menstrual Disorder Centre and provide
important information about a treatment for a
common condition of women worldwide.
▪ The design is rigorous: a double-blind, double-
dummy, randomised controlled trial powered to
compare three active treatments.
▪ The primary outcome effect size of the difference
between groups is robust.
▪ Owing to funding limitations, the study was
implemented in two phases under two different
randomisation schemes and data from the first
phase were analysed prior to the implementation
of the second phase.
▪ Stratified analyses were conducted to account for
any differences between the results of the two
phases of the trial.
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and distress that are the major symptoms of dysmenor-
rhoea.5 6 The pain duration is commonly 8–72 h and is
usually associated with the onset of menstrual flow.1
The condition often results in activity restriction over
1–3 days of each menstrual cycle,3 and therefore the
annual costs in terms of disability, in addition to treat-
ment, are high.
The two most common treatments in the USA for dys-
menorrhoea are non-steroidal anti-inflammatory drugs
(NSAIDs) and oral contraceptives (OCs).7 NSAIDs are
effective for some but not all women, with a failure rate
of up to 25%.8 Both treatments require multiple or daily
dosing and have side effects. In China, common treat-
ments for dysmenorrhoea include acupuncture and
herbal preparations, with increased use of NSAIDs in
recent years; OCs are seldom prescribed for the
condition.
Injection of an agent, usually a herbal extract or drug,
into an acupuncture point is an innovation in Traditional
Chinese Medicine (TCM)6 9 and has been used in China
over the past 40 years.10 Classical and modern acupunc-
ture usually involves needles inserted at multiple points
and left in place for 20–60 min. In contrast, acupuncture
point injection is easily administered and standardised,
and requires less time at the clinical encounter.11
Acupuncture point injection of vitamin K3 has been
used as a standard of care treatment for dysmenorrhoea
at the Menstrual Disorder Centre at the Obstetrics and
Gynecology Hospital in Shanghai, People’s Republic of
China, since at least 1985,12 and several uncontrolled
studies of the treatment have been conducted in China
and Italy with various forms of vitamin K.13–15 While
vitamin K3 has been administered consistently at the
clinic where this study was conducted,16 this form of
vitamin K is not typically used in the USA and Europe.
Vitamin K1, however, is routinely administered to new-
borns shortly after birth to augment coagulation and is
considered to be safe. A pilot study of the acupuncture
point injection treatment with a cross-over design substi-
tuted vitamin K1 for vitamin K3 and explored the
acceptability of the treatment in the USA and the
absorption of vitamin K1.17 18
While the positive results of these prior studies are
promising, it was unknown whether vitamin K as an
agent and the acupuncture point as the site of injection
were essential to the treatment’s effect and whether
together they were an optimal treatment for pain relief
of primary dysmenorrhoea as compared with other
injection treatments. To address this question, the
primary objective of this study was to compare: (1) the
effects of vitamin K injection in a non-acupuncture
point, (2) the effects of injection of a non-active sub-
stance in the acupuncture point, and (3) the combined
effects of vitamin K injected in the acupuncture point.
In addition, we sought to evaluate whether the treat-
ments, given only once, relieve menstrual pain at a
variety of time points; and to evaluate the feasibility of
conducting an international randomised trial with a
comparative effectiveness design. Our secondary out-
comes were whether the treatments administered in a
single cycle had a carryover effect and decreased men-
strual pain, distress and the need for medications over
six cycles.
MATERIALS AND METHODS
Written informed consent was obtained from young
women, and assent and parental consent from girls and
their families. The study was conducted in accordance
with the requirements of Good Clinical Practice.
We conducted a double-blind, double-dummy, rando-
mised controlled trial with three parallel groups:
Group A saline acupuncture point injection: Study partici-
pants randomised to this group received normal saline
injection at the San Yin Jiao or Spleen 6 (SP6) acu-
puncture point (both legs) and saline in the right
buttock. This served as an active control for vitamin K.
Group B vitamin K deep muscle injection: Study partici-
pants randomised to this group received a vitamin K3
injection in the right buttock and saline at a non-
acupuncture point near but not SP6 (both legs). The
clinicians located the sham point at 1 cm above Sp6,
1 cm towards the back of the leg from Sp6, and pene-
trated the needle 1 cm beneath the skin. This served as
an active control for the acupuncture point injection
site and ensured that the patients in this group had
the same dose of vitamin K3 as group C, albeit at a dif-
ferent injection site.
Group C vitamin K acupuncture point injection: Study parti-
cipants randomised to this group received a vitamin K3
injection at the SP6 point (both legs) and saline in the
right buttock. A third injection of saline in the buttock
was administered to maintain uniformity of treatment
with groups A and B.
The treatments were administered only once.
The alternative hypothesis to all treatments having
similar effects on pain of primary dysmenorrhoea is that
pain relief in group C—the treatment most closely
aligned with TCM theory and clinical innovations at the
Menstrual Disorder Centre—was optimal compared with
the other two treatments.
Young Chinese women aged 14–25 years with severe
primary dysmenorrhoea for at least 6 months that had
not been relieved, or only partially relieved, by any other
treatment were recruited for this study. A four-grade
scale which grades dysmenorrhoea as absent, mild, mod-
erate or severe based on the presence of cramps,
whether or not the cramps were very painful or caused
patients to sometimes or always cut back on activities,19
was used to screen prospective participants to determine
eligibility. Young women enrolled in the study were nul-
liparous, Mandarin or Shanghainese speaking, with
regular menstrual cycles for the past 6 months, and who
had a working phone.
Exclusion criteria were diagnosis of secondary dysmen-
orrhoea, the use of OCs, intrauterine devices or
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anticoagulant drugs, pregnancy, history of abdominal
surgery, participation in other therapies for acute or
chronic pain and diagnosis of dysmenorrhoea due to
any recognised cause, such as pelvic inflammatory
disease. In addition, women who had had previous injec-
tion treatment with vitamin K in SP6 for any reason or
who were intolerant to NSAIDs or who planned to be
out of the area during the course of the 7-month study
were excluded.
Study participants were recruited from patients who
presented with pelvic pain at the Menstrual Disorder
Centre at the Obstetrics and Gynecology Hospital,
Fudan University, in Shanghai, China. Information ses-
sions were conducted at Fudan University to let young
women and providers know about the study at the clinic.
Study physicians and staff screened prospective women
and girls for eligibility and interest, described the study
details and obtained consent. For women under the age
of 18, parental consent was also obtained. Diagnosis of
primary dysmenorrhoea was confirmed by the study phy-
sicians on the basis of history and physical examination.
Prospective participants who were not currently in pain
signed consent forms and were told to return at the
onset of their next painful menstrual cycle. Participants
could also consent and receive the treatment on their
initial visit if they were currently in pain due to menses.
Participants were informed that they could withdraw
from the study at any time.
Treatments were administered only once by medical
doctors who were also experienced acupuncturists. Pain
measurement was conducted by clinic staff and not the
study physicians. Participants were followed for 6 months
with follow-up phone interviews by clinic staff.
Treatment consisted of an injection at each of three sites
as per group assignment. A single injection of vitamin
K3 is 4 mg/mL, so since participants were injected once
in each leg, the total dose was 8 mg of vitamin K3 or
2 mL of saline solution. The SP6 acupuncture point is
located on the lower leg, 3 ‘cun’ or four widths of the
middle phalange of the index finger on the patient,
proximal to the peak of the medial malleolus, just along
the posterior aspect of the tibial bone. The muscle
injected was m. soleus (see figure 1). An injection of
8 mg of vitamin K3 or 2 mL saline (depending on the
group) was administered as a deep intramuscular injec-
tion in the glutaeal muscle of the right buttock. NSAIDs
were available in case any patient was not satisfied with
pain relief from the treatment after 1 h.
Vitamin K3 was used because it is and has been the
agent used in the Menstrual Disorder Centre at the
Obstetrics and Gynecology Hospital for treatment of
primary dysmenorrhoea. Vitamin K3 ampoules were pre-
pared by the Shanghai #1 Biochemical and
Pharmaceutical Company, Ltd. The investigators visited
the company in January 2004 to specify a design for
blinding (packaging, coding and labelling) of the
ampoules. Vitamin K3 and saline ampoules looked iden-
tical. The injection site was specified on the ampoules.
The randomisation list was created by a biostatistician,
who went to the certified research pharmacy, which
encapsulated the agents to blind the treatment and then
sent the ampoules to the research site. Eligible consent-
ing participants were assigned to a group at the treat-
ment visit according to a randomly permuted block
design with blocks of size 6 to ensure equal allocation of
patients to each treatment group. The randomisation
scheme was generated and held by the study
biostatisticians.
Physicians were blinded as to saline and vitamin K3,
but they knew whether they were injecting into the acu-
puncture point or near the acupuncture point. Thus,
study physicians knew when they were administering to
group B, but they could not differentiate the treatments
in groups A and C. Patients presumably did not know
the difference between the acupuncture point and near
the acupuncture point and were blinded as to the agent
in all three groups. Evaluators (study staff collecting
pain measures and other study data) did not know the
group assignment of participants.
Baseline data were collected following consent and
prior to treatment. The primary outcome, change in
pain intensity at 0 and 60 min, was recorded on an
11-unit Numeric Rating Scale (NRS) from 0 to 10 with 0
being no pain and 10 being the worst pain the partici-
pant could imagine. Pain scores were obtained at base-
line and at 2, 5, 30 and 60 min post-injection. A
secondary outcome was the consumption of analgesic
Figure 1 In two of the groups injections were in the Spleen
6 (SP6)/San Yin Jiao (SYJ) acupuncture point near the ankle
on both legs. In the third group the injection site was near but
not on SP6.
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tablets during the menstrual cycle before and after the
injection treatment. Menstrual-related symptoms, such
as hours in bed and time lost from school or work, were
recorded at baseline and after treatment. Participants’
menstrual distress was evaluated after each menstrual
cycle on two different scales: Cox Retrospective
Symptom Scale (over 6 cycles) and Moos Menstrual
Distress Questionnaire (MMDQ) (over 2 cycles).20 21
The Cox scale included 17 symptoms commonly asso-
ciated with menstrual distress. Each of these was rated by
the participant on both intensity and duration with a
range from 0 (not perceptible) to 4 (extremely upset-
ting). The MMDQ assessed six symptoms: muscle stiff-
ness, headache, cramps, backache, fatigue and general
aches and pains—each on a range of 0 (not present) to
4 (severe). A questionnaire to assess patients’ expect-
ation about group assignment and attitude towards par-
ticipation in the research study was also administered.
The trial was conducted in two phases. The first phase
was conducted as an exploratory pilot with 12 partici-
pants randomised to each of the three groups. The
results of the pilot were positive, with the effect size for
group C exceeding the hypothesised clinical effect when
compared with the other groups. For the second phase,
the investigators conducted a power calculation based
on the effect sizes of the primary outcome from the
pilot phase. Using a Bonferroni correction for multiple
testing, we estimated that with 26 patients in each group,
we could detect change in mean pain scores of 2 units
with SDs of 2.0 between groups at α=0.05 and 95%
power. A stratified analysis was planned to accommodate
the two phases of the randomised study.
Continuous variables were summarised by descriptive
statistics: mean, SD, median and range. Categorical vari-
ables were summarised in terms of frequencies and per-
centages and groups were tested to see if they differed
on population characteristics. Initially, results from the
two phases of the trial were tested in stratified analyses,
however, the results were parallel and homogeneous
with no significant difference between the stratified and
unstratified results, so the data were then combined in
the analysis for reporting. Treatment differences
between the three groups were compared both in
marginal-effect and mixed-effect models using Stata V.11
(College Station, Texas, USA). A linear mixed-effects
model was applied for the primary outcome, where pain
scores at time 0 (baseline) and 60 min were the two
response variables (per participant), each of which had
its own interceptor representing the average pain level
at that time point.22 23 The observed covariates were
treatment modalities and each individual was assigned
with an unobserved random effect. The treatment effect
is the difference at the 60 min time point between the
two arms under consideration. Significance levels were
obtained and adjusted for multiple comparisons using
Scheffe and Tukey-Kramer methods.22 Analysis of vari-
ance (ANOVA) was used to compare mean differences
both (1) BETWEEN and (2) WITHIN groups on the
secondary outcomes of the Cox and MMDQ scores for
cycles 1 and 2 and also for cycles 1 and 7.
RESULTS
Baseline data
The study initiated in October 2004 and ended in June
2010. Phase I was completed in 2 years as it was National
Institutes of Health (NIH) funded and physicians had
release time to conduct the study: phase II took four
additional years to complete. Young Chinese women pre-
senting with severe pelvic pain to an urban hospital
clinic who were willing to be randomised to active treat-
ments were screened for eligibility and signed consent
forms. The parents of girls under 18 also consented to
have their children participate. Of the 124 women
screened, 82 enrolled in the study and were randomised,
80 of whom completed all study visits (see figure 2). Two
women withdrew after they signed consent forms and
were randomised, because they or their parents changed
their minds about participation in a research study. The
baseline demographic characteristics and menstrual
cycle profiles of the women did not differ between the
three groups (see table 1).
Reduction of pain: When treated with an acupuncture
point injection of vitamin K3 in SP6 (group C), partici-
pants had an average 6.6 point decrease in pain on the
NRS (from 8.0 to 1.5, p<0.001) within 60 min after injec-
tion. The average pain decreased by 4.9 points (from
7.9 to 3.0, p<0.001) in the saline acupuncture point
injection group (group A) and 4.7 points (from 8.0 to
3.3, p<0.001) in the vitamin K3 deep muscle injection
group (group B) (see figure 3).
Difference in group effects: On average, the hypothesised
optimal treatment reduced pain by 1.6 and 1.7 units
more than in the other groups. Changes in NRS mea-
sured pain between group A (active control) and group
B (active control) were less than 1 unit (−0.71, CI −1.37
to −0.05) and not significant, but the differences in
average scores between group C (hypothesised to be
optimal) and both group A (1.11, CI 0.45 to 1.78) and
group B (1.82, CI 1.45 to 2.49) were statistically signifi-
cant in the unadjusted and adjusted mixed-effects
models (see table 2).
Secondary outcomes were the effects on pain intensity
and duration of menstrual symptoms for six follow-up
cycles: both within-group/between-cycle and mean dif-
ferences between groups were compared. Menstrual dis-
tress was reduced in all post-treatment cycles within all
groups. For the two cycles (2 and 7) we compared with
baseline, all groups had significant differences
(p<0.001) between the baseline cycle (cycle 1) and the
post-treatment cycle (cycle 2) on the Cox Duration and
Cox Intensity scores. All groups also showed a significant
difference (p<0.001) between the baseline scores of
menstrual distress and cycle 7 scores at the 6-month
follow-up report (see table 3). On the long-term mea-
sures, significant differences of paired comparisons were
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not observed between groups (cycles 1 and 2 and cycles
1 and 7) on the Cox Duration and Intensity measures. A
significant difference however (p<0.001) was observed
between groups on the severity of the six symptoms as
measured by the MDDQ cycles 1 and 2.
Sixty minutes after the treatment and in the follow-up
cycles, participants were free to take oral rescue medica-
tion (naproxen) if they felt it to be necessary. One tablet
of 250 mg of naproxen is a standard treatment for pelvic
pain at the Menstrual Disorder Centre. Seven partici-
pants in group B, three participants in group A and two
participants in group C asked for and received 250 mg
naproxen orally more than 1 h after the injection treat-
ment and after their pain measurements were recorded.
Analgesic tablet consumption during each menstruation
period was recorded and is detailed in table 4. In all
follow-up cycles, all three groups consumed fewer oral
analgesic tablets compared with what they reported at
baseline.
Adverse events reported by four participants (2 in
group A, and 1 in groups B and C) included mild dis-
comfort at the injection site that was self-limited and did
not require additional medication. Follow-up surveys
included questions to assess feasibility of study proce-
dures and expectancy among participants. After partici-
pating in the study, the majority of participants (65.0%)
found the study procedures very or somewhat satisfac-
tory. Thirty-five per cent found them somewhat unsatis-
factory but none found them very unsatisfactory, and all
participants thought that their participation would help
other women with menstrual pain.
Participants were asked whether they thought they
had received injection at the true acupuncture point
and whether they had received vitamin K3. The majority
Figure 2 Flow of participants
through the study (SP6, Spleen 6;
SYJ, San Yin Jiao).















Mean±SD Mean±SD Mean±SD p Value
Age at start of study Years 22.5±2.2 20.5±3.2 20.7±2.9 0.098
Age at menarche Years 14.3±1.1 13.7±1.0 13.3±1.2 0.075
Shortest cycle Days 26.5±2.5 26.8±3.2 26.5±2.6 0.935
Longest cycle Days 33.2±4.6 32.1±3.4 31.9±4.0 0.652
Duration of menstrual flow Days 5.7±0.9 5.9±1.0 5.7±1.0 0.763
Missed school or work Days 1.8±0.4 1.8±0.4 1.9±0.5 0.781
Extra time spent in bed Hours 5.5±3.1 7.7±4.9 7.1±2.0 0.241
Typical worst pain* NRS† 0–10 7.88±0.62 8.20±0.41 8.00±0.65 0.953
*Typical worst pain is the patient’s assessment of what is usual for them to experience during an episode of menstrual pelvic pain.
†NRS where 0 equals no pain and 10 equals the worst pain the rater can possibly imagine.
NRS, Numeric Rating Scale.
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indicated that they did not know which treatment they
received (68.8% and 57.5%) and the majority of the
remainder thought they had received injection at the
true acupuncture point (30.0%) as well as vitamin K3
(36.3%). Only a small proportion thought they had
received a control treatment: 1.3% thought they had
received an injection near the acupuncture point and
6.3% thought they had received saline. These results
suggest that the blinding procedures were effective.
DISCUSSION
All three active treatments reduced menstrual cycle pain
rapidly (within an hour) with minimal side effects, but
acupuncture point injection with vitamin K3 in SP6 was
found to be optimal, producing a greater clinical and
statistically significant reduction in pain. One to two
units on the NRS for pain has been described as clinic-
ally significant by studies designed to evaluate unit
scores with clinical improvement.24 25 Acupuncture
point injection with vitamin K3 provided rapid relief of
severe as well as moderate pain due to dysmenorrhoea.
Effective treatment can be administered in a high-
volume hospital clinic and may be especially useful to
women whose pain is unmitigated by other methods. No
differences between groups were found on long-term
effects, but at the end of the study, participants in all
active treatment groups endured significantly less pain
over a reduced duration and reported fewer activity
restrictions, fewer hours in bed and the consumption of
fewer drugs for menstrual pain over the course of six
cycles than at baseline, indicating the value of injection
treatments for primary dysmenorrhoea. All three treat-
ments reduced pain rapidly during the treatment cycle,
yet the treatment in standard use at the clinic, injection
of vitamin K3 in SP6, was clearly more effective than the
other two treatments on the primary short-term
outcome.
The pattern of reduction of menstrual distress over
the follow-up cycles is consistent. Women in all of the
treatment groups experienced long-term relief.
Differences between the three groups on the secondary
long-term outcomes of menstrual distress were not sig-
nificant. Patterns of analgesic use may interact with
scores of menstrual distress. In this study, group B, for
example, consumed more analgesics than the other two
groups. Future research should take this into account
when building analytic models. The sensitivity of the
Cox and MMDQ scales over the long follow-up period is
Figure 3 Pain intensity at
baseline and in the first hour after
treatment (SP6, Spleen 6).
Table 2 Pain intensity at baseline and in the first hour after treatment
Overall model F-value=14.47 (p<0.001)











A vs B −0.708 0.338 −2.095 0.037 0.113 0.093
A vs standard 1.113 0.34 3.269 0.001 0.005 0.003
B vs standard 1.821 0.341 5.341 <0.001 <0.001 <0.001
Group A: Saline in Spleen 6 (SP6) bilaterally and in the buttock (active control for vitamin K).
Group B: Vitamin K off-point bilaterally and in the buttock (active control for point location).
Group C: Vitamin K in SP6 bilaterally and in the buttock (standard at the Menstrual Disorder Centre).
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unknown. Both instruments were administered with the
idea of validating results from one to the other and
determining the best instrument for future research.
The MMDQ scale may be more sensitive than the Cox
scale for long-term follow-up assessment.
The overall reduction of menstrual distress and the
decrease in the need for analgesics across groups during
the follow-up period is notable. Whether these effects
are due to the treatment or to the natural course of dys-
menorrhoea over 6 months is unknown, but merits
further study. Differences between the effects of the
three treatments on menstrual distress in subsequent
cycles were more variable than the short-term pain
outcome and may be obscured by the use of pain medi-
cations and other home remedies which participants
were free to employ during the long follow-up period.
The three-arm study was designed to control for mul-
tiple effect pathways, and therefore the results support
the injection site (an acupuncture point) as a crucial
aspect of optimal pain relief. Little information exists
about any specific mechanism of acupuncture’s effect on
menstrual pain, and while acupuncture’s interruption of
pain pathways has been investigated since 1979,26 much
remains unknown about the cause and magnitude of the
effects of acupuncture, as placebo-controlled trials of
manual treatments are difficult to evaluate. Many studies
of acupuncture do not find significant difference of
effects for off-point and on-point stimulation with acu-
puncture needles.27 28 Point injection may have different
effects than classical acupuncture, and measurement of
outcomes may not have been sensitive enough in some
previous studies to determine optimal effects.29 Benefits
of acupuncture point injection may include rapid and
substantial pain relief and prolonged effects across a
variety of pain conditions.30–32 The three injection treat-
ments administered in this study worked rapidly, perhaps
quicker than NSAIDs, which optimises at 1–2 h,33 34 and
our study indicates that the treatment may have long-term
Table 3 Menstrual distress before and after injection treatment and during follow-up cycles





Study period Mean Mean Mean Per cent Mean SD
Baseline cycle 1
Group A (control for vitamin K) 1.42 1.19 1.20 96.30 6.52 3.95
Group B (control for point location) 1.40 1.18 1.38 100.00 6.67 4.26
Group C (standard†) 1.29 1.18 1.34 100.00 7.58 5.38
Treatment cycle 2
Group A (control for vitamin K) 0.84‡ 0.68‡ 0.69 59.26 3.60 1.35
Group B (control for point location) 0.93‡ 0.68‡ 0.82 74.07 5.40 2.80
Group C (standard†) 0.83‡ 0.69‡ 0.69§ 61.54 4.57 1.81
Cycle 3
Group A (control for vitamin K) 0.85 0.66 n/a 65.38 4.33 1.30
Group B (control for point location) 0.93 0.76 n/a 62.96 5.00 1.85
Group C (standard†) 0.73 0.57 n/a 50.00 5.13 2.47
Cycle 4
Group A (control for vitamin K) 0.90 0.65 n/a 42.31 7.50 5.73
Group B (control for point location) 0.82 0.67 n/a 55.56 5.00 1.61
Group C (standard†) 0.76 0.64 n/a 46.15 5.11 1.76
Cycle 5
Group A (control for vitamin K) 0.77 0.52 n/a 42.31 7.67 5.99
Group B (control for point location) 0.78 0.66 n/a 55.56 5.11 1.76
Group C (standard†) 0.76 0.57 n/a 57.69 3.60 0.52
Cycle 6
Group A (control for vitamin K) 0.84 0.66 n/a 61.54 8.14 3.18
Group B (control for point location) 0.93 0.77 n/a 66.67 5.45 1.81
Group C (standard†) 0.87 0.63 n/a 57.69 4.91 1.38
Cycle 7
Group A (control for vitamin K) 0.79¶ 0.60¶ n/a 57.69 4.89 2.03
Group B (control for point location) 0.98¶ 0.78¶ n/a 59.26 5.25 1.82
Group C (standard†) 0.77¶ 0.61¶ n/a 50.00 5.50 2.39
*Although all three groups experienced reduction in menstrual distress on the Cox and MMDQ scales between baseline and cycle 2 and
between baseline and cycle 7, the only significant difference in group means was on the MMDQ scale between baseline and cycle 2.
†Standard treatment at the Menstrual Disorders Centre, Obstetrics and Gynecology Hospital, Shanghai.
‡Significant difference (p<0.001) between baseline cycle and treatment cycle within group paired comparisons.
§Significant difference (p<0.001) between groups A and C and between groups B and C on menstrual distress.
¶Significant difference (p<0.001) between baseline cycle and last follow-up cycle within group paired comparisons.
MMDQ, Moos Menstrual Distress Questionnaire; n/a, not applicable.
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effects on menstrual distress of up to 6 months. An effect
of up to 3 months has been observed in at least one previ-
ous study.14 Although this treatment cannot be self-
administered, it does not require dosing prior to the
onset of worst symptoms, as NSAIDs do, and nor does it
require daily dosing as OCs do.
Our results also indicate that vitamin K3 may have
some role in amelioration of menstrual pain, although
the mechanism is as yet unclear, as none of the forms of
vitamin K are known to have analgesic effects. At least
one form of vitamin K is absorbed through this treat-
ment: increased concentrations of vitamin K1 (phyllo-
quinone) following injection at SP6 were observed in a
study of four participants with primary dysmenor-
rhoea.18 Analysis of plasma phylloquinone indicated
non-detectable concentrations before acupuncture point
injection with vitamin K1, which increased up to
425 nmol/L, 20–48 h following injection. The vitamin K
profile of women with menstrual cycle disorders may be
worth exploring in a nutritional approach to dysmenor-
rhoea prevention.
The use of vitamin K3 (menadione) for this treatment
is routine at the Menstrual Disorder Centre at the
Obstetrics and Gynecology Hospital where this study was
conducted.14 16 Studies in the USA and Europe have
tested alternate forms of vitamin K. Vitamin K1 (phyl-
loquinone) and K4 (menaquinone-4) were chosen over
vitamin K3 because of availability in the clinical setting
and because vitamin K1 has a better safety profile than
vitamin K3.35 These studies also found that menstrual
pain and distress were relieved.14 15 17 Little is known
about vitamin K’s role in ameliorating symptoms of dys-
menorrhoea or difference in effect in the administration
of the various forms of vitamin K. NSAIDs alleviate the
pain of menstrual cramps through their effect on prosta-
glandin levels. One study that measured prostaglandin
levels after acupuncture using the point SP6 did not
find that the treatment reduced them.6 To the best
of our knowledge, studies of vitamin K and prostaglan-
din levels have not been reported. However, vitamin K
is being explored for its potential role in reducing
proinflammatory cytokines.36 Vitamin K is typically used
clinically to abet blood clotting and, recently, has been
studied in relation to bone health. Animal studies have
shown that ovary concentrations of vitamin K are higher
than in other organs,37 and researchers have suggested
that vitamin K may play a role in reproductive
endocrinology.38
Our overarching goal was to create a research agenda
leading to a larger comparative effectiveness study con-
ducted by international collaborators in three countries,
and the study reported here was conceived as necessary
preliminary research to an international trial of acupunc-
ture point injection of vitamin K in SP6 vs NSAIDs, which
would be executed in the three countries where pilot
research had been successfully conducted. Studies in
Europe, North America and Asia have indicated that this
treatment reduces menstrual pain in young women with
primary dysmenorrhoea, in a variety of outpatient set-
tings in diverse cultures. The results of these studies as a
group indicate that various forms of vitamin K (K1, K4
and K3) can produce pain relief when utilised with acu-
puncture point injection and have also indicated that the
treatment is adaptable to various clinical settings (public
health clinics, private practice, hospital outpatient facil-
ities) and acceptable to young women in North America
and Europe, as well as in China.14–17 The study reported
here is one of two known randomised studies of the treat-
ment17 and has the largest sample size and most rigorous
design of all known studies on the treatment. Results
reported here also suggest that both the agent and site of
injection influence the effect size of the short-term pain
reduction measures.
Study limitations
The study setting may limit generalising the results.
Expectation by Chinese women that acupuncture will
provide pain relief may have influenced reports of pain
reduction. However, this limitation is mitigated by the
research efforts of international collaborators who have
implemented the clinical protocol in a variety of coun-
tries and settings. The hypothesised optimal treatment
in this study has been tested on Chinese, American and
Italian women with primary dysmenorrhoea and has
reduced menstrual pain in young women in public
health clinics, private practice and hospitals.14 15 17 The
study was implemented in two phases under two differ-
ent randomisation schemes and data from the first
phase were analysed prior to the implementation of the
second phase of the study. Initially, the study team com-
pleted a pilot study of 36 patients and analysed the data.
Since the hypothesised results were positive and the
effect size was robust, the study was powered and data
were collected for another 44 patients for more stable
results. We performed analysis stratified by the two
phases and found no significant differences in results by
phase, which supports our methodological approach of
analysing and reporting the combined results. Menstrual
distress scores on two different scales were compared











Mean (SD) Mean (SD) Mean (SD)
Baseline 0.93 0.82 0.82 0.56 0.89 0.77
Cycle 2 0.22 0.42 0.41 0.57 0.27 0.45
Cycle 3 0.11 0.32 0.33 0.48 0.35 0.49
Cycle 4 0.22 0.42 0.41 0.5 0.27 0.45
Cycle 5 0.22 0.42 0.48 0.5 0.35 0.49
Cycle 6 0.33 0.48 0.48 0.58 0.23 0.43
Cycle 7 0.22 0.42 0.33 0.48 0.23 0.43
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with Student t tests and not in an adjusted model for
multiple comparisons.
The study took over 6 years to complete in a very busy
outpatient clinic. Recruitment during the second phase
of the study became ever more challenging. Whereas
the first phase received external funding, in the second
phase the funding was greatly reduced, limiting the
release time of the study physicians and making the
6 months of follow-up data collection difficult.
Scheduling difficulties also affected recruitment, as it is
important for participants to be treated within 2 days of
onset of menses and at the height of their pain.
However, this was not always possible, and this limited
participation in the study.
CONCLUSION
Our study reports the effect of acupuncture point injec-
tion of vitamin K3 on the pain of dysmenorrhoea in
young Chinese women. It extends the work of previous
single-arm and cross-over studies through the implemen-
tation of a randomised parallel group design, and pro-
vides substantial evidence that the treatment provides
pain relief for women with painful periods who have not
been able to obtain satisfactory relief by any other
method. Study results also indicate that the site of injec-
tion and the specific agent of vitamin K, specifically
vitamin K3, are crucial to the optimal treatment of pain
due to primary dysmenorrhoea.
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